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Prescription for antidepressant in reducing
future alcohol-related readmission in
patients suffering from depression and
alcohol use disorder: a retrospective
medical record review
Patrick Chan4*, Katie Yomen1, Jennifer Turcios2 and Mark Richman3
Abstract
Background: Patients suffering from major depressive disorder are more likely to suffer from alcohol use disorder.
The data is inconclusive for the effectiveness of antidepressant treatment of patients suffering from both illnesses
in regards to improving sobriety and reducing alcohol-related healthcare expenses such as hospitalizations. The
objective of this study is to determine if a new prescription of an antidepressant upon inpatient discharge is
associated with a reduction in the number of future acute alcohol-related hospital readmissions to the same
institution in patients suffering from major depressive disorder and alcohol-use disorder.
Methods: A retrospective, medical record review study was conducted at a publicly-supported hospital in Sylmar,
CA. A query was performed for adult patients admitted between 1/1/2005–12/31/2013 who had ICD-9 codes for
both alcohol-use disorder and depression. Index admission was the first hospitalization in which the patient was
currently consuming alcohol and had depression as identified by physician documentation as a problem. Acute
alcohol-related admissions were those for alcohol intoxication or withdrawal (indicating current alcohol use).
Patients were excluded if they were receiving an antidepressant on index admission, <18 years old, no patient
data available, or not currently consuming alcohol; 139 patients met inclusion criteria. Multivariate logistical regression
analysis was performed on the primary predictive variable of discharge prescription of an antidepressant along
with other independent variables for alcohol readmissions: homelessness, family history of alcohol use disorder,
and smoking.
Results: Discharging patients with a prescription of an antidepressant was not associated with a reduction in acute
alcohol-related readmission. There was no difference in acute alcohol-related readmissions between patients discharged
with (44.6 %) versus without (47.0 %) a prescription for an antidepressant (p = 0.863). The median number of days
between index admission and first readmission for those discharged on an antidepressant was 141 days while those
who were not was 112 days (p= 0.284).
Conclusion: Discharging patients suffering from both alcohol-use disorder and major depressive disorder with a
prescription for an antidepressant is not associated with a reduction in future readmissions, nor significantly increase
the number of days to readmission. The study does not support the concept of antidepressants in reducing acute
alcohol-related readmissions.
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Background
Major depressive disorder (MDD) and alcohol abuse
continue to plague patients and society. In the United
States, MDD is a mood disorder affecting millions of
people with a lifetime prevalence of 16.2, and 7.6 %
Americans suffering from moderate to major depressive
symptoms within the past two weeks [1, 2]. The National
Institute on Alcohol Abuse and Alcoholism estimated that
18 million Americans suffered from alcohol use disorder
(AUD) in 2007, with a 12-month prevalence of 14 % and
life prevalence of 29 % [2, 3]. Futhermore, MDD and AUD
co-occur at high rates [4]. The National Institute on
Alcohol Abuse and Alcoholism’s National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC)
indicated that patients who suffer from MDD are more
likely to suffer from AUD [3], and conversely, those who
suffer from alcohol use disorder have a 12 month preva-
lence of MDD of 16.4 % [5]. For patients suffering from
either MDD or AUD, they face numerous challenges in
improving their health [6]. For patients who suffer from
MDD and AUD concomitantly, the situation becomes
much more daunting. Alarmingly, it has been estimated
that only 6 % of patients suffering from mental disorders
and substance abuse receive treatment from proper
medical or mental health care providers in the past six
months [7]. The abuse of alcohol is costly, estimated
around $25 billion due to health care, crime, and lost
productivity [8].
Treatment for AUD is generally initiated during alco-
hol withdrawal or hospitalization due to an alcohol-
related complication. Pharmacotherapeutic options for
the treatment of AUD include naltrexone, disulfiram,
and acamprosate, in addition to psychosocial treatment
[9, 10]. Naltrexone and acamprosate act as deterrents to
alcohol consumption. Effective MDD treatment involves
both psychotherapy and pharmacotherapy. Pharmacologic
options for depression treatment are selective serotonin
reuptake inhibitors (SSRIs), serotonin norepinephrine
reuptake inhibitors (SNRIs), tricyclic antidepressants
(TCAs), and monoamine oxidase inhibitors (MAOIs).
While the efficacy between the classes of SSRIs and
TCAs is similar, SSRIs are frequently prescribed due
to a favorable side-effect profile and fewer drug inter-
actions compared to TCAs. One concern with SSRIs
is the risk of serotonin syndrome, a life-threatening ad-
verse reaction which may cause hyperthermia, mental
confusion, and myoclonus. MAOIs have largely been
avoided due to drug-drug and drug-food interactions.
There is a link between MDD and AUD. Depression is
a strong predictor for first incidence of AUD [11]. Treat-
ment of patients diagnosed with both MDD and AUD
are less successful than patients with MDD or AUD only
[12, 13]. Consensus clinical practice guidelines from the
American Psychiatric Association are available for the
treatment of AUD [14] and MDD [15] individually. The
current data is inconclusive for the effectiveness of
antidepressant treatment of patients suffering from
both illnesses in regards to improving sobriety and
reducing alcohol-related healthcare expenses such as
hospitalizations. Mixed results from clinical trials have
been reported in the treatment of patients suffering
from concurrent MDD and AUD. Patients treated
with chlordiazepoxide and imipramine [16, 17], nefa-
zodone [18], sertraline [19, 20], citalopram [21], and
TCAs [22] were unsuccessful in reducing alcohol con-
sumption. In contrast, other trials using desipramine
[23], fluoxetine [24], sertraline [25], and nefazodone
[26] demonstrated a decrease in alcohol use amongst
patients. Thus, it is unclear whether antidepressant
use in patients suffering from alcohol and depression
is effective in improving actual sobriety. A meta-
analysis of 11 placebo-controlled randomized trials
conducted by Iovieno, et. al. on the treatment of co-
occurring depression and alcohol dependence showed
that imipramine, desipramine, and nefazodone were
most effective for reducing depressive symptoms;
however, the data on the efficacy of antidepressants
on sobriety was inconclusive due to the limited num-
ber of studies analyzing this effect [27].
In recent years there has been a shift in treatment
paradigm. More recent studies have employed combin-
ation therapy with medications from different pharma-
cological classes. Patients treated with memantine and
escitalopram [28] or aripiprazole and escitalopram [29]
showed better outcomes than patients treated with only
escitalopram. Both serotonin and dopamine neurotransmit-
ter systems have demonstrated dysfunctional neurome-
chanisms in patients suffering from alcohol dependence
[30]. Aripiprazole is a partial antagonist for dopamine re-
ceptors in addition to being an agonist at 5-HT2A (5-hy-
droxytryptamine; serotonin) receptor. This is the rationale
for the addition of aripiprazole to the treatment of patients
who are suffering from both MDD and AUD. A study by
Pettinati et al. demonstrated higher alcohol abstinence rates
in patients treated with both sertraline and naltrexone [31].
However, polytherapy may expose patients to a greater
number of side effects or drug interactions.
Studies have identified several risk factors for alcohol-
related admissions [32]. A prospective cohort trial fo-
cused on risk factors for alcohol-related outcomes
such as hospitalization and deaths. Males and social
factors such as marital status (single or divorced/
widowed), low socioeconomic status, and patients
who consumed higher amounts of alcohol per week
or cigarettes per day, were associated with an in-
creased risk [32, 33]. Homelessness and family his-
tory of alcohol-use disorder were identified to also
elevate the risk of alcohol consumption, resulting in
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an increased risk in the number of alcohol-related
admissions [34].
Because of the limited pharmacological options
available for the treatment of AUD, it has become
pivotal to examine if any of the currently available
medications may have an effect in reducing alcohol-
related readmissions in patients who are suffering
from both MDD and AUD.
Objectives
This retrospective study aims to add to the literature re-
garding whether a newly initiated prescription for an
antidepressant in patients suffering from depression and
alcohol-use disorder is related to a reduced rate of
subsequent acute alcohol-related hospital readmissions.
A decrease in the number of these readmissions would
lower the high economic burden caused by AUD. Clinical
evidence of effectiveness demonstrated by antidepressants
would provide physicians another compelling indication
for prescribing antidepressants to patients with both
conditions upon discharge.
Methods
Setting
A retrospective, medical record review study conducted
at Olive View- University of California, Los Angeles
Medical Center (OVMC), a 377-licensed bed, publicly-
supported, academic teaching hospital located in Sylmar,
CA. It is staffed to 200 beds, serves a medically-indigent
population, and functions as a teaching hospital without
cardiothoracic, neurosurgical, or inpatient orthopedic
services. Olive View’s Emergency Department has ap-
proximately 55,000 annual visits, and the hospital admits
approximately 15,000 patients annually.
Study design and patients
A query was conducted to identify patients admitted to
the hospital between 1/1/2005-12/31/2013 with an ICD-
9 code for both alcohol-use disorder and depression
prior to, or at the time of, admission. Patients were ex-
cluded if they were currently receiving an antidepressant
on index admission, <18 years old, patient data was not
available, or if the patient stated that they did not con-
sume alcohol within 72 h of admission as noted in the
history and physical in medical records. A total of 139
patients were included for electronic medical record re-
view by two independent reviewers. Patient information
was collected at both index admission and subsequent
hospital readmissions. Index admission was defined as
the first hospitalization in which the patient was cur-
rently consuming alcohol and had current depressive
symptoms. Current consumption of alcohol was defined
as having an alcoholic beverage within 72 h of hospital
admission. Patients were considered to have current
depressive symptoms if there were any physician docu-
mentation during index admission of depression as an
active problem. Subsequent readmissions were considered
if the discharge diagnosis documented acute intoxication
of alcohol, alcohol withdrawal, or acute alcohol-related
complication (altered mental status related to alcohol con-
sumption, cirrhosis, alcoholic cardiomyopathy, and gastri-
tis) as noted during the medical record review. During the
index admission, the following patient data was collected:
demographics, social history (substance abuse disorder and
AUD), length of stay (LOS), clinical information, co-morbid
disease states, and medication history (specifically anti-
depressant use prior to admission, during hospitalization,
and at discharge). Selective serotonin reuptake inhibitors
(SSRI’s; fluoxetine, fluvoxamine, sertraline paroxetine, esci-
talopram, and citalopram), tricyclic antidepressants (TCA’s;
amitriptyline, clomipramine, desipramine, doxepin, imipra-
mine, and nortriptyline), atypical antidepressants (bupro-
pion, duloxetine, venlafaxine, mirtazapine, and trazodone),
and monoamine oxidase inhibitors (MAOI’s; phenelzine,
tranylcypromaine, and selegiline) were considered prescrip-
tions if noted specifically in medical records as indicated
for depression. Literature-identified demographic risk fac-
tors for alcohol-related hospital admissions (homelessness,
smoking, and family history of AUD) were also recorded.
At each subsequent hospital readmission, data such as
LOS, antidepressant use before, during, and after discharge,
and current alcohol consumption were noted. The primary
analysis is focused on whether a prescription for antide-
pressants is associated with a reduced rate of alcohol-
related readmissions in patients suffering from depression
and AUD. Secondary outcomes included differences in
LOS or intervals between readmissions. This study was IRB
approved by Western University of Health Sciences and
Olive-View Medical Center.
Statistical analysis
The primary independent variable for the model is a
prescription for antidepressant upon discharge. Other
independent variables included in the model were the
following demographic variables: gender, homelessness,
current smoker, and family history of AUD. The Chi-
square and Fisher’s Exact Tests were used to analyze
baseline characteristics. The Mann–Whitney test was
used to analyze non-normally distributed continuous
data such as LOS and time between index admission
and first readmission. A multivariate logistic regression
analysis with a dichotomous outcome of being readmit-
ted was performed by SPSS (Version 22.0) to analyze the
predictive effects of each independent variable and re-
ported as odds ratios and 95 % confidence intervals. All
independent variables were included in the model simul-
taneously. Two-tailed p values were considered, a priori,
statistically significant at p < 0.05.
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Results
Baseline characteristics of the 139 patients that were in-
cluded (discharged on an antidepressant, n = 56; dis-
charged without an antidepressant, n = 83) in the study
are shown in Table 1. The average age was 47 years old
in both groups (SD = 9 in those discharged with an anti-
depressant; SD = 8 in those discharged without an anti-
depressant); approximately 70 % of patients were male.
Patients who had a history of antidepressant use, but not
at the time of index admission, were more likely to be
discharged with a prescription for an antidepressant. No
difference in social factors such as smoking, family his-
tory of AUD, and current illicit substance abuse was
found between both groups at baseline. The most com-
mon comorbidity found among those discharged with
versus those discharged without an antidepressant was
cirrhosis. There was no statistical significance found
between both groups in the number of comorbidities
(Table 1). Alcohol-related reasons prompting index ad-
mission and readmissions are listed in Table 2.
The primary outcome (Table 3) showed no significant
difference in acute alcohol-related readmissions between
patients discharged with versus without a prescription
for an antidepressant. Over the study interval, those dis-
charged with a prescription for an antidepressant had
between 1 and 4 (median = 1) acute alcohol-related read-
missions; for those discharged without a prescription,
this range was 1 to 12 (median = 1) readmissions. The
most common antidepressant class prescribed by physi-
cians was the selective-serotonin reuptake inhibitors
(SSRIs), including citalopram (19.6 %), fluoxetine (19.6 %),
sertraline (17.9 %), escitalopram (14.3 %), paroxetine
(8.9 %). The next most-commonly prescribed classes were
atypical antidepressants [mirtazapine (10.7 %), trazodone
(1.8 %)], followed by tricyclic antidepressants [amitriptyl-
ine (3.6 %) and nortriptyline (1.8 %)]. The least-prescribed
class was SNRIs (venlafaxine = 1.8 %). Due to availability
of medications on formulary, SSRIs are most frequently
prescribed.
The multivariate logistical regression model did not
show any statistical significance for prescriptions for
an antidepressant upon discharge, gender, homeless-
ness, family history, or smoking (Table 3). There was
no difference in readmission rates between patients
discharged with prescriptions for SSRIs versus other
antidepressants (40 % versus 54 %, Chi-square test =
0.58, d.f. = 1, p = 0.53).
Patients discharged with a prescription for an anti-
depressant had a longer LOS (median (IQR): 4 days (4–
7.5 days) versus 3 days (2–5 days), Mann–Whitney exact
test p = 0.10, and higher number of days between index
admission and first readmission (median (IQR): 141 days
(30–526 days) versus 112 days (27–244 days), Mann–
Whitney exact test p = 0.28.
Discussion
Patients with both MDD and AUD who were initiated
and discharged from an inpatient stay with an antidepres-
sant prescription had similar readmission rates and inter-
vals between readmissions compared with patients of
Table 1 Patient characteristics
Baseline Characteristics Discharged with Antidepressant
(n = 56)
Discharged without Antidepressant
(n = 83)
P-value (d.f.) Test statistic
Gender - Male, n (%)* 40 (71 %) 58 (70 %) 0.84 (1) 0.04
Age in years (mean ± SD)*** 47 (±9) 47 (±8) 0.77 (137) 1.24
Homeless, n (%)* 8 (14 %) 19 (23 %) 0.21 (1) 2.58
Current smoker, n (%)* 18 (32 %) 26 (31 %) 0.91 (1) 0.01
Family history of alcohol abuse, n (%)* 7 (13 %) 13 (16 %) 0.60 (1) 0.27
Current illicit substance abuse, n (%)* 6 (11 %) 15 (18 %) 0.23 (1) 1.41
Prior antidepressant use, n (%)* 30 (54 %) 16 (19 %) <0.0001 (1) 17.76
Number of comorbidities (mean ± SD)*** 0.54 (+/−0.57) 0.75 (+/−0.75) 0.29 (137) 1.07
Asthma, n (%)** 0 (0 %) 5 (6.1 %) 0.08 (1) 0.08
Chronic obstructive pulmonary disease, n (%)** 1 (1.8 %) 1 (1.2 %) >0.99 (1)
Cirrhosis, n (%)* 16 (28.6 %) 31 (37.3 %) 0.28 (1) 1.15
Congestive heart failure, n (%)** 2 (3.6 %) 2 (2.4 %) 0.90 (1)
Diabetes mellitus, n (%)* 7 (12.5 %) 11 (13.3 %) >0.99 (1) 0.02
Malignancy, n (%)** 3 (5.3 %) 2 (2.4 %) 0.39 (1)
Schizophrenia, n (%)** 1 (1.8 %) 0 (0 %) 0.40 (1)
Stroke, n (%)** 0 (0 %) 3 (3.6 %) 0.27 (1)
*Chi-Squared test P-value; **Fisher-Exact test P-value; ***Unpaired t-test P-value; ***; SD standard deviation
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similar demographics and comorbidities discharged with-
out an antidepressant prescription. Approximately 40 % of
patients with both MDD and AUD were discharged with
an antidepressant.
A previous meta-analysis showed antidepressant ther-
apy does not significantly reduce depressive symptoms
among all patients with both MDD and AUD [27]. The
meta-analysis suggested that SSRIs were ineffective.
However, TCAs, in particular imipramine and desipra-
mine, and nefazodone, were more effective in treating
depressive symptoms.
Prior studies demonstrated treating patients suffering
from both MDD and AUD with chlordiazepoxide and
imipramine [16, 17], nefazodone [18], sertraline [19, 20],
and TCAs [22] did not reduce alcohol consumption.
Our analysis did not examine the effectiveness of
Table 2 Alcohol-related reasons for index admissions and readmissions
Reasons for Index Admission Discharged with Antidepressant
(n = 56)
Discharged without
Antidepressant (n = 83)
P-value
(d.f.)
Test
statistic
Alcohol withdrawal, n (%)* 31 (55.4 %) 41 (49.4 %) 0.49 (1) 0.47
Acute alcoholic hepatitis, n (%)* 13 (23.2 %) 23 (27.7 %) 0.55 (1) 0.35
Complications of cirrhosis (ascites, jaundice,
encephalopathy), n (%)*
11 (19.6 %) 25 (30.1 %) 0.17 (1) 1.91
Gastritis, n (%)* 6 (10.7 %) 11 (13.3 %) 0.65 (1) 0.20
Acute alcohol intoxication, n (%)** 4 (7.1 %) 13 (15.1 %) 0.19 (1)
Gastrointestinal bleed, n (%)* 6 (10.7 %) 10 (12.0 %) 0.81 (1) 0.06
Suicidal ideation, n (%)* 7 (12.5 %) 6 (7.2 %) 0.30 (1) 1.10
Chest pain, n (%)** 4 (7.1 %) 6 (7.2 %) >0.99 (1)
Other, n (%)** 10 (17.9 %) 7 (8.4 %) 0.10 (1)
Reasons for Readmission Discharged with Antidepressant
(n = 25)
Discharged without
Antidepressant (n = 39)
P-value
(d.f.)
Test
statistic
Alcohol withdrawal, n (%)* 10 (40.0 %) 27 (69.2 %) 0.28 (1) 1.15
Acute alcoholic hepatitis, n (%)* 6 (24.0 %) 8 (20.5 %) 0.74 (1) 0.11
Complications of cirrhosis (ascites, jaundice,
encephalopathy), n (%)**
4 (16.0 %) 6 (15.4 %) 0.44 (1)
Gastrointestinal bleed, n (%)** 4 (16.0 %) 7 (17.9 %) >0.99 (1)
Gastritis, n (%)** 7 (28.0 %) 3 (7.7 %) 0.04 (1)
Acute alcohol intoxication, n (%)** 4 (16.0 %) 4 (10.3 %) 0.70 (1)
Suicidal ideation, n (%)** 2 (8.0 %) 4 (10.3 %) >0.99 (1)
Chest pain, n (%)** 0 (0.0 %) 1 (2.6 %) >0.99 (1)
Other, n (%)** 1 (4.0 %) 3 (7.7 %) >0.99 (1)
*Chi-Squared test P-value; **Fisher-Exact test P-value
Table 3 Independent variables predicting readmission for alcohol abuse (n = 139)
Characteristic % Readmitted OR (95 % CI) P-value (d.f.) Test statistica
Male (n = 98) 45.9 1
Female (n = 41) 46.3 1.006 (0.475–2.127) 0.99 (1) 0.00
Smoking (n = 44) 43.2 1
Non-smoking (n = 95) 47.4 1.152 (0.549–2.416) 0.71 (1) 0.14
Family History (n = 20) 50.0 1
No Family History (n = 119) 45.4 0.823 (0.317–2.137) 0.69 (1) 0.16
Homeless (n = 27) 40.7 1
Not Homeless (n = 112) 47.3 1.291 (0.532–3.133) 0.57 (1) 0.32
Prescription for antidepressant upon discharge at index admission
Yes (n = 56) 44.6 1
No (n = 83) 47.0 1.115 (0.561–2.219) 0.76 (1) 0.10
aWald test in the multivariate logistic regression model; OR odds ratio, CI confidence interval
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antidepressants on reducing actual alcohol consumption.
However, the lack of an association between discharging
patients with an antidepressant and a reduction in future
alcohol-related readmission reinforces this observation.
Nevertheless, antidepressant use should not be dis-
couraged in patients with MDD and AUD, as antidepres-
sant therapy is helpful in reducing depressive symptoms
in this patient population. Furthermore, unresolved de-
pression is a major factor in relapsing to alcohol use
[35]. It is important for healthcare professionals to deter-
mine the primary cause of a patient’s alcohol problems,
as there are many etiologies. Healthcare providers
should consider the strong link between depression and
alcohol use disorder; 13.7 % of patients suffering from
depression also consume alcohol over a 12-month
period [36]. In this population, antidepressants may be
warranted since the underlying cause of their alcohol
use disorder is depression. Furthermore, a recent meta-
analysis indicates that patients who suffer from inde-
pendent depression with concomitant AUD show greater
improvements in their depressive symptoms [37]. Two
additional reviews also support this notion that anti-
depressant therapy is more effective in independent de-
pression [38, 39].
We observed an increase in LOS among patients
discharged with versus without an antidepressant pre-
scription. Antidepressants require several weeks to
take effect, so no immediate improvement in mood
that might facilitate discharge should be expected.
Side-effects emerge more quickly. Increasing LOS
among patients prescribed antidepressants might be
explained by the possibility that such patients may
have had more severe depression prompting inpatient
evaluation or delaying discharge. While the interval to
next admission was not statistically-different between
the two groups, the larger interval suggests that anti-
depressants may be effective for reducing the time to
readmission. In a larger study population, a significant
difference might be observed.
We investigated whether discharge with an antidepres-
sant prescription modified the effect of literature-identified
demographic risk factors for alcohol-related readmissions.
Known readmission demographic factors include smoking,
family history of alcohol-use disorder, homelessness, and
adherence to outpatient alcohol counseling [32, 34, 40].
Our model included these demographic variables except
adherence to outpatient alcohol counseling due to the lack
of such notation in inpatient medical records. The results
(Table 3) from the multivariate model showed no statistical
differences in any of the demographic factors for alcohol re-
lated readmissions between patients with versus those with-
out the risk factors.
One strength of the current study is the extensive time
period examined (2005–2013) and the inclusion of
multiple literature-identified risk factors (homelessness,
smoking, and family history of alcohol abuse) in the
multivariate model. Nonetheless, this study has several
limitations. First, it was a single-institution study utiliz-
ing a retrospective approach. Retrospective studies may
lack data and some patients may have been lost in
follow-up. Therefore, our study was relatively small and
the patient sample comprised of only patients in the sur-
rounding geographical area. The ability to include vari-
ous institutions would encompass a more robust and
diverse sample generalizable to the overall U.S. popula-
tion and increase the likelihood of determining whether
any variables approaching statistical significance are
truly significant. It would also address another limitation
by assessing whether patients were admitted to other
hospitals, which this study was unable to do. It is also
possible that a bias may exist in the group receiving a
prescription for an antidepressant. Patients who have
more severe depressive symptoms may be more likely to
receive a prescription for an antidepressant, and may
also be more likely to be readmitted in the future for an
alcohol-related event. The current work did not examine
the severity of depressive symptoms between the two
study groups nor was it able to differentiate if patients
had independent depression or substance-induced de-
pression. An additional limitation was lack of means to
assess whether patients received other forms of depres-
sion therapy (i.e., psychotherapy). The current study did
not assess clinical outcomes, such as changes in depres-
sive symptoms or changes in AUD. These therapies are
effective in treating both MDD and AUD. Finally, it was
not determined whether a patient discharged with a pre-
scription for an antidepressant actually filled the pre-
scription or complied with the medication regimen. This
is a concern, as non-compliance with antidepressant
therapy is often high due to either the patient experien-
cing side-effects to the medication or stopping the medi-
cation due to the stigma associated with having
depression [41]. In addition, economic factors can pro-
hibit patients’ ability to pay for medications [42].
Failure to identify a reduction in alcohol-related read-
missions may indicate the complexity of managing dual-
diagnosis patients, particularly those with medical comor-
bidities. Simply prescribing an antidepressant medication
to a patient with AUD is unlikely to significantly interrupt
the complex chain of events leading to alcohol-related
readmissions. Doing so is best accomplished in the con-
text of a medical home model for management of com-
plex, chronic diseases [33]. Such a model would include:
 Reliable, timely access to high-quality primary care
 Insurance coverage for medications
 Referral to and enrollment in substance abuse
programs
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 Provision of “wrap-around services, including
social services, psychotherapy, and substance
abuse treatment)
 Integration of physical health, behavioral/mental
health, and substance abuse services in a
co-management or co-location arrangement
Conclusions
Discharge with an antidepressant in patients suffering
from both MDD and AUD was not associated with
lower acute alcohol-related readmission rates. However,
antidepressants may still be helpful in patients suffering
from independent depression co-occurring with AUD.
Healthcare providers should continue to be aggressive
and employing strategies in treating AUD in patients
also suffering from MDD. Studies with a larger, more
generalizable population may shed light on whether anti-
depressants affect emergency department or inpatient
utilization.
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